Pulmonary Sarcoidosis
Conditions
Keywords
Influenza Vaccine, Sarcoidosis, Antibody
Brief summary
The purpose of this study is to determine the efficacy of influenza vaccine (antibody response) in patients with sarcoidosis.
Detailed description
Sarcoidosis is a multisystem disease with unclear etiology characterized by the presence of noncaseating granuloma\[1\]. T helper cells response is exaggerated at the site of disease and cellular immunity depressed in peripheral blood\[2\]. Cutaneous anergy, lymphopenia and inversion of CD4/CD8 ratio in peripheral blood suggest T helper cells involvement\[3\]. The action of humeral immune system in sarcoidosis is a matter of controversy. Standard hepatitis B virus vaccination did not provoke protective antibody titer in patients with sarcoidosis\[3\]. Although antibody response against influenza vaccine in patients with sarcoidosis is not well described, this vaccine is highly recommended in patients with chronic pulmonary diseases such as asthma, COPD and fibrosis \[4, 5, 6\]. In this study we aim to evaluate the humeral response to the influenza vaccine in sarcoidosis patients and assess vaccine safety.
Interventions
BIOLOGICALInfluenza Vaccine
One 0.5 ml dose of influenza vaccine injected intramuscular.
Sponsors
Shahid Beheshti University of Medical Sciences
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
Sarcoidosis patients: * Patients with relevant clinical, radiologic and histologic features of sarcoidosis (all stages). * Signed informed consent.
Exclusion criteria
* Organ failure (kidney, heart, liver). * Collagen vascular diseases. * Diabetes. * Contraindications of vaccine (Egg allergy). * Patients who receive high dose (\> 60 mg/day) steroid therapy. * Any acute disease. * Conditions accompanied by immunosuppression (like organ transplantation, HIV). * Any psychological disease that interferes with regular follow-up. * Inoculation with influenza vaccine within the past 5 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serologic Response (equal or more than 4 fold HI titer rise) to each of the 3 antigens of the trivalent vaccine of the 2008-9 influenza vaccine | 4-6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Magnitude of change in the antibody titer against each of the 3 antigenes of the trivalent vaccine of the 2008/2009 season [A/Brisbane/59/2007(HIN1)-like virus;A/Brisbane/10/2007(H3N2)-like virus;B/Florida/4/2006-like virus] | 4-6 weeks |
| Protective Antibody (equal or more than 1:40) titer after vaccination | 4-6 weeks |
| Vaccine Safety (any major or minor side effects) | 2 months |
Countries
Iran
Outcome results
None listed